Belgium· BE-AMP-SAM596151-00
Vyepti 100 mg
A eptinezumab product containing eptinezumab, registered in Belgium by H. Lundbeck. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Eptinezumab is registered in 14 of 19 countries.
Countries holding a registration under ATC N02CD05 (eptinezumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Eptinezumab · ATC N02CD05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Eptinezumab
- Manufacturer
- H. Lundbeck
- Country
- Belgium (BE)
- ATC code
- N02CD05
- ATC class
- Eptinezumab
- Defined daily dose
- 1.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb4495271
- be_apb7740293
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Eptinezumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandVYEPTIAbacus Medicine A/S
- CzechiaVYEPTIH. Lundbeck A/S, Valby
- IrelandVYEPTI 100 mg concentrate for solution for infusionH. Lundbeck A/S
- IcelandVyeptiH. Lundbeck A/S*
- NorwayVyeptiH. Lundbeck A/S
- SwedenVyepti 100 mg Koncentrat till infusionsvätska, lösningH. Lundbeck A/S
- United StatesVyeptiLundbeck Pharmaceuticals LLC
- CanadaVYEPTILUNDBECK CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Vyepti
- Norway · Vyepti
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4941c969-153b-4306-8c81-ab9d8d4906ff GET /v1/drugs/4941c969-153b-4306-8c81-ab9d8d4906ff?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Vyepti 100 mg",
"name_fr": "Vyepti 100 mg",
"name_nl": "Vyepti 100 mg",
"amp_code": "SAM596151-00",
"strengths": [
"100.0000",
"100.0000",
"40.5000",
"40.5000"
],
"pack_count": 2,
"substances": [
"Eptinezumab",
"Sorbitol",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Eptinezumab",
"authorisation_numbers": [
"EU/1/21/1599/001",
"EU/1/21/1599/002"
]
}See everything about eptinezumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.